114672-01-4

Usage

Uses

Used in Fragrance and Flavor Industry:
Ethyl 1-benzylcyclobutanecarboxylate is used as a fragrance ingredient for its sweet, floral aroma, contributing to the scent profiles of various products in the fragrance and flavor industry.
Used in Cosmetic and Personal Care Products:
In the cosmetic and personal care industry, ethyl 1-benzylcyclobutanecarboxylate is used as a fragrance ingredient to enhance the sensory experience of products such as perfumes, soaps, and detergents.
Used in Pharmaceutical Synthesis:
Ethyl 1-benzylcyclobutanecarboxylate is utilized in the synthesis of pharmaceuticals, acting as a precursor in organic chemistry reactions, which highlights its importance in the development of new medications.
Used in Research and Development:
As a chemical compound with unique properties, ethyl 1-benzylcyclobutanecarboxylate is also used in research and development settings to explore its potential applications and reactions in various chemical processes.
It is crucial to handle ethyl 1-benzylcyclobutanecarboxylate with care due to its potential to cause irritation to the skin, eyes, and respiratory system. Proper safety measures, including the use of a well-ventilated environment, should be implemented during its handling and application.

Upstream product

• 100-39-0 benzyl bromide 
• 35120-18-4 ethyl 1-bromocyclobutane-1-carboxylate 
• 62673-31-8 benzyl(bromo)zinc 
• 14924-53-9 ethyl cyclobutylcarboxylate 
• 97-62-1 Ethyl isobutyrate 

Downstream Products

• 1255306-38-7 1-benzylcyclobutanecarbonyl azide 
• 114672-02-5 1-benzylcyclobutane-1-carboxylic acid 
• 568591-06-0 {(S)-1-[Hydroxy-((R)-1-phenyl-ethylcarbamoyl)-methyl]-pentyl}-carbamic acid 1-benzyl-cyclobutylmethyl ester 
• 433219-87-5 (1-benzyl-cyclobutyl)-methanol 

Relevant academic research and scientific papers

Formation of quaternary carbons through cobalt-catalyzed C(sp3)-C(sp3) Negishi cross-coupling

Formation of all-carbon-substituted quaternary carbons is a key challenge in organic and medicinal chemistry. We report a cobalt-catalyzed C(sp3)-C(sp3) cross-coupling that allows for the introduction of benzyl, heteroarylmethylzinc and allyl groups to halo-carbonyl substrates. The cross-coupling reaction is selective for C(sp3)-over C(sp2)-halides, in contrast to most used catalytic metals, and allows access to novel scaffolds of pharmaceutical interest. NMR mechanistic studies suggest the presence of Co(0) complexes as catalytic species. This journal is

(ALPHA-SUBSTITUTED CYCLOALKYLAMINO AND HETEROCYCLYLAMINO) PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN TREATING PROLIFERATIVE DISEASES

Provided herein are (alpha-substituted cycloalkylamino or heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, e.g., a compound of Formula I, and their pharmaceutical compositions, preparation, and use as agents or drugs for treating proliferative diseases.

CYCLOBUTENEDIONE DERIVATIVES

The present invention relates to compounds of the formula (I): to pharmaceutically acceptable salts therefore and to pharmaceutically acceptable solvates of said compounds and salts, wherein the substituents are defined herein; to compositions containing such compounds; and to the uses of such compounds in the treatment of various diseases, particularly inflammatory conditions.

Potent and selective P2-P3 ketoamide inhibitors of cathepsin K with good pharmacokinetic properties via favorable P 1′, P1, and/or P3 substitutions

A series of ketoamides were synthesized and evaluated for inhibitory activity against cathepsin K. Exploration of the interactions between achiral P2 substituents and the cysteine protease based on molecular modeling suggestions resulted in potent cathepsin K inhibitors that demonstrated high selectivity versus cathepsins B, H, and L. Subsequent modifications of the P3, P1, and P1′ moieties afforded orally bioavailable inhibitors. A series of ketoamides were synthesized and evaluated for inhibitory activity against cathepsin K. Exploration of the interactions between achiral P2 substituents and the cysteine protease based on molecular modelling suggestions resulted in potent cathepsin K inhibitors that demonstrated high selectivity versus cathepsins B, H, and L. Subsequent modifications of the P3, P1, and P1′ moieties afforded orally bioavailable inhibitors.